{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:54:43Z","timestamp":1777517683893,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Carboxylesterase 1 (<jats:italic>CES1<\/jats:italic>) hydrolyzes the prodrug clopidogrel to an inactive carboxylic acid metabolite. The effects of <jats:italic>CES1<\/jats:italic> S75N (rs2307240,C&gt;T) on clopidogrel response among 851 acute coronary syndrome patients who came from the north, central and south of China were studied. The occurrence ratios of each endpoint in the CC group were significantly higher than in the CT\u2009+\u2009TT group for cerebrovascular events (14% vs 4.8%, p\u2009&lt;\u20090.001, OR\u2009=\u20090.31), acute myocardial infarction (15.1% vs 6.1%, p\u2009&lt;\u20090.001, OR\u2009=\u20090.37) and unstable angina (62.8% vs 37.7%, p\u2009&lt;\u20090.001, OR\u2009=\u20090.36). The results showed that there was a significant association between <jats:italic>CES1<\/jats:italic> S75N (rs2307240) and the outcome of clopidogrel therapy. Moreover, the frequency of the T allele of rs2307240 in acute coronary syndrome patients (MAF\u2009=\u20090.22) was more than four times higher than that in the general public (MAF\u2009=\u20090.05).<\/jats:p>","DOI":"10.1038\/s41598-017-07736-1","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T15:32:56Z","timestamp":1501255976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients"],"prefix":"10.1038","volume":"7","author":[{"given":"Fei-Yan","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Quan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Lian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"7736_CR1","doi-asserted-by":"crossref","unstructured":"Levine, G. N. et al. 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. CIRCULATION (2016).","DOI":"10.1161\/CIR.0000000000000404"},{"key":"7736_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1517\/14656566.2012.666524","volume":"13","author":"M Karazniewicz-Lada","year":"2012","unstructured":"Karazniewicz-Lada, M., Danielak, D. & Glowka, F. Genetic and Non-Genetic Factors Affecting the Response to Clopidogrel Therapy. Expert Opin Pharmacother. \n                           13, 663\u2013683 (2012).","journal-title":"Expert Opin Pharmacother."},{"key":"7736_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner, A. R. et al. Association of Cytochrome P450 2C19 Genotype with the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy. JAMA. \n                           302, 849\u2013857 (2009).","journal-title":"JAMA."},{"key":"7736_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1021\/tx2004085","volume":"25","author":"PM Dansette","year":"2012","unstructured":"Dansette, P. M., Rosi, J., Bertho, G. & Mansuy, D. Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, Whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer. Chem Res Toxicol. \n                           25, 348\u2013356 (2012).","journal-title":"Chem Res Toxicol."},{"key":"7736_CR5","first-page":"147","volume-title":"Clin Pharmacokinet.","author":"XL Jiang","year":"2015","unstructured":"Jiang, X. L., Samant, S., Lesko, L. J. & Schmidt, S. Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. Clin Pharmacokinet. \n                           54, 147\u2013166 (2015)."},{"key":"7736_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00216-011-5147-4","volume":"401","author":"L Silvestro","year":"2011","unstructured":"Silvestro, L. et al. Development and Validation of an HPLC-MS\/MS Method to Quantify Clopidogrel Acyl Glucuronide, Clopidogrel Acid Metabolite, and Clopidogrel in Plasma Samples Avoiding Analyte Back-Conversion. Anal Bioanal Chem. \n                           401, 1023\u20131034 (2011).","journal-title":"Anal Bioanal Chem."},{"key":"7736_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1124\/jpet.106.110577","volume":"319","author":"M Tang","year":"2006","unstructured":"Tang, M. et al. Antiplatelet Agents Aspirin and Clopidogrel are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel is Transesterificated in the Presence of Ethyl Alcohol. J Pharmacol Exp Ther. \n                           319, 1467\u20131476 (2006).","journal-title":"J Pharmacol Exp Ther."},{"key":"7736_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/phar.1194","volume":"33","author":"SC Laizure","year":"2013","unstructured":"Laizure, S. C., Herring, V., Hu, Z., Witbrodt, K. & Parker, R. B. The Role of Human Carboxylesterases in Drug Metabolism: Have we Overlooked their Importance? Pharmacotherapy. \n                           33, 210\u2013222 (2013).","journal-title":"Pharmacotherapy."},{"key":"7736_CR9","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1124\/dmd.109.028498","volume":"37","author":"K Hagihara","year":"2009","unstructured":"Hagihara, K. et al. A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation From Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel. Drug Metab Dispos. \n                           37, 2145\u20132152 (2009).","journal-title":"Drug Metab Dispos."},{"key":"7736_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/0091270009343005","volume":"50","author":"NA Farid","year":"2010","unstructured":"Farid, N. A., Kurihara, A. & Wrighton, S. A. Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans. J Clin Pharmacol. \n                           50, 126\u2013142 (2010).","journal-title":"J Clin Pharmacol."},{"key":"7736_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/molecules13020412","volume":"13","author":"M Hosokawa","year":"2008","unstructured":"Hosokawa, M. Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs. Molecules. \n                           13, 412\u2013431 (2008).","journal-title":"Molecules."},{"key":"7736_CR12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/infdis\/jiq145","volume":"203","author":"D Shi","year":"2011","unstructured":"Shi, D., Yang, D., Prinssen, E. P., Davies, B. E. & Yan, B. Surge in Expression of Carboxylesterase 1 During the Post-Neonatal Stage Enables a Rapid Gain of the Capacity to Activate the Anti-Influenza Prodrug Oseltamivir. J Infect Dis. \n                           203, 937\u2013942 (2011).","journal-title":"J Infect Dis."},{"key":"7736_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.abb.2012.04.010","volume":"522","author":"MK Ross","year":"2012","unstructured":"Ross, M. K., Borazjani, A., Wang, R., Crow, J. A. & Xie, S. Examination of the Carboxylesterase Phenotype in Human Liver. Arch Biochem Biophys. \n                           522, 44\u201356 (2012).","journal-title":"Arch Biochem Biophys."},{"key":"7736_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/clpt.2012.13","volume":"92","author":"EK Tarkiainen","year":"2012","unstructured":"Tarkiainen, E. K. et al. Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans. Clin Pharmacol Ther. \n                           92, 68\u201371 (2012).","journal-title":"Clin Pharmacol Ther."},{"key":"7736_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","volume":"23","author":"JP Lewis","year":"2013","unstructured":"Lewis, J. P. et al. The Functional G143E Variant of Carboxylesterase 1 is Associated with Increased Clopidogrel Active Metabolite Levels and Greater Clopidogrel Response. Pharmacogenet Genomics. \n                           23, 1\u20138 (2013).","journal-title":"Pharmacogenet Genomics."},{"key":"7736_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/dmd.108.024943","volume":"37","author":"HJ Zhu","year":"2009","unstructured":"Zhu, H. J. & Markowitz, J. S. Activation of the Antiviral Prodrug Oseltamivir is Impaired by Two Newly Identified Carboxylesterase 1 Variants. Drug Metab Dispos. \n                           37, 264\u2013267 (2009).","journal-title":"Drug Metab Dispos."},{"key":"7736_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/FPC.0000000000000035","volume":"24","author":"C Xie","year":"2014","unstructured":"Xie, C. et al. The Effects of CES1A2 A(\u2212816)C and CYP2C19 Loss-Of-Function Polymorphisms On Clopidogrel Response Variability Among Chinese Patients with Coronary Heart Disease. Pharmacogenet Genomics. \n                           24, 204\u2013210 (2014).","journal-title":"Pharmacogenet Genomics."},{"key":"7736_CR18","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1002\/jps.21376","volume":"97","author":"S Takahashi","year":"2008","unstructured":"Takahashi, S., Katoh, M., Saitoh, T., Nakajima, M. & Yokoi, T. Allosteric Kinetics of Human Carboxylesterase 1: Species Differences and Interindividual Variability. J Pharm Sci. \n                           97, 5434\u20135445 (2008).","journal-title":"J Pharm Sci."},{"key":"7736_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/jpet.112.201640","volume":"344","author":"HJ Zhu","year":"2013","unstructured":"Zhu, H. J. et al. Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation. J Pharmacol Exp Ther. \n                           344, 665\u2013672 (2013).","journal-title":"J Pharmacol Exp Ther."},{"key":"7736_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nm.2281","volume":"17","author":"HJ Bouman","year":"2011","unstructured":"Bouman, H. J. et al. Paraoxonase-1 is a Major Determinant of Clopidogrel Efficacy. NAT MED. \n                           17, 110\u2013116 (2011).","journal-title":"NAT MED."},{"key":"7736_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1124\/mol.107.036889","volume":"72","author":"J Yang","year":"2007","unstructured":"Yang, J., Shi, D., Yang, D., Song, X. & Yan, B. Interleukin-6 Alters the Cellular Responsiveness to Clopidogrel, Irinotecan, and Oseltamivir by Suppressing the Expression of Carboxylesterases HCE1 and HCE2. Mol Pharmacol. \n                           72, 686\u2013694 (2007).","journal-title":"Mol Pharmacol."},{"key":"7736_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/cpt.101","volume":"97","author":"EK Tarkiainen","year":"2015","unstructured":"Tarkiainen, E. K. et al. Carboxylesterase 1 C.428G\u2009>\u2009a Single Nucleotide Variation Increases the Antiplatelet Effects of Clopidogrel by Reducing its Hydrolysis in Humans. Clin Pharmacol Ther. \n                           97, 650\u2013658 (2015).","journal-title":"Clin Pharmacol Ther."},{"key":"7736_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1515\/dmdi-2014-0009","volume":"29","author":"Z Merali","year":"2014","unstructured":"Merali, Z., Ross, S. & Pare, G. The Pharmacogenetics of Carboxylesterases: CES1 and CES2 Genetic Variants and their Clinical Effect. Drug Metabol Drug Interact. \n                           29, 143\u2013151 (2014).","journal-title":"Drug Metabol Drug Interact."},{"key":"7736_CR24","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. CES1 Genetic Variation Affects the Activation of Angiotensin-Converting Enzyme Inhibitors. PHARMACOGE-NOMICS J. (2015).","DOI":"10.1038\/tpj.2015.42"},{"key":"7736_CR25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/dmd.115.068536","volume":"44","author":"J Shi","year":"2016","unstructured":"Shi, J. et al. Sacubitril is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation is Affected by CES1 Genetic Variation. Drug Metab Dispos. \n                           44, 554\u2013559 (2016).","journal-title":"Drug Metab Dispos."},{"key":"7736_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ajhg.2008.04.015","volume":"82","author":"HJ Zhu","year":"2008","unstructured":"Zhu, H. J. et al. Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis. Am J Hum Genet. \n                           82, 1241\u20131248 (2008).","journal-title":"Am J Hum Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-07736-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-07736-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-07736-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T07:55:41Z","timestamp":1671782141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-07736-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["7736"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-07736-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]},"assertion":[{"value":"6 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7244"}}